Type i interferons [ifnα, β, δ, κ, ω, τ, il-28a (ifnΛ2) il-28b (ifnΛ3) and il-29 (ifnΛ1)]

The Cytokine Handbook

Volumn , Issue , 2003, Pages 549-566

  Soos, Jeanne M ^a   Szente, Brian E ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 7644238550     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1016/B978-012689663-3/50027-2     Document Type: Chapter

References (200)

1. Abramovich C., Shulman L.M., Ratoviski E., et al. Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and an associated surface protein in response to IFNα and IFNβ. EMBO J. 1994, 13:5871-5877.
2. Alimena G., Morra E., Lazzarino M., et al. Interferon alpha 2b as therapy for Ph-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 1988, 72:642-647.
3. Arnason B.G. Interferon beta in multiple sclerosis. Clin. Immunol. Immunopathol. 1996, 81:1-11.
4. Arnheiter H., Frese M., Kambadur R., et al. Mx transgenic mice-animal models of health. Curr. Topics Microbiol. Immunol. 1995, 206:119-147.
5. Aviles A., Duque G., Talavera A., Guzman R. Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival. Leuk. Lymphoma 1996, 20:459-499.
6. Balachandran S., Kim C.N., Yeh W.C., et al. Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling. EMBO J. 1998, 17:6888-6902.
7. Balachandran S., Roberts P.C., Kipperman T., et al. Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/caspase-8 death signaling pathway. J. Virol. 2000, 74:1513-1523.
8. Bart R.S., Porzio N.R., Kopf A.W., et al. Inhibition of growth of B16 murine malignant melanoma by exogenous interferon. Cancer Res. 1980, 40:614-619.
9. Bass B.L., Weintraub H., Cattaneo R., Billeter M.A. Biased hypermutation of viral RNA genomes could be due to unwinding/modification of double-stranded RNA. Cell 1989, 56:331-335.
10. Bazan J.F. Shared architecture of hormone binding domains in type I and II interferon receptors. Cell 1990, 61:753-754.
11. Biron C.A. Interferons α and β as immune regulators-a new look. Immunity 2001, 14:661-664.
12. Biron C.A., Nguyen K.B., Pien G.C., et al. Natural killer cells in antiviral-defense: function and regulation by innate cytokines. Ann. Rev. Immunol. 1999, 17:189-220.
13. Borden E.C. Innovative treatment strategies for non-Hodgkin’s lymphoma and multiple myeloma. Semin. Oncol. 1994, 21:14-22.
14. Butterfield J., Gleich G.J. Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann. Intern. Med. 1994, 121:648-653.
15. Cantell K., Pirhonen J. IFN-gamma enhances production of IFN-alpha in human macrophages but not in monocytes. J. IFN Cytokine Res. 1996, 16:461-463.
16. Chebath J., Benech P., Revel M., Vigneron M. Constitutive expression of (2’-5’) oligo A synthetase confers resistance to picornavirus infection. Nature 1987, 330:587-588.
17. Chill J.H., Nivasch R., Levy R., et al. The human interferon receptor: NMR-based modeling, mapping of the IFN-α2 binding site, and observed ligand-induced tightening. Biochem. 2002, 41:3575-3585.
18. Chin Y.E., Kitagawa M., Su W.C., et al. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 1996, 272:719-722.
19. Chong K.L., Feng L., Schappert K., et al. Human p68 kinase exhibits growth suppression in yeast and homology to the translational regulator GCN2. EMBO J. 1992, 11:1553-1562.
20. Choubey D., Gutterman J.U. Inhibition of E2F-4/DP-1-stimulated transcription by p202. Oncogene 1997, 15:291-301.
21. Choubey D., Lengyel P. Binding of an interferon-inducible protein (p202) to the retinoblastoma protein. J. Biol. Chem. 1995, 270:6134-6140.
22. Choubey D., Li S.J., Datta B., et al. Inhibition of E2F-mediated transcription by p202. EMBO J. 1996, 15:5668-5678.
23. Chu W.M., Ostertag D., Li Z.W., et al. JNK2 and IKKβ are required for activating the innate response to viral infection. Immunity 1999, 11:721-731.
24. Coccia E.M., Romeo G., Nissim A., et al. A full-length murine 2-5A synthetase cDNA transfected in NIH 3T3 cells impairs EMCV but not VSV replication. Virol. 1990, 179:228-233.
25. tyk2 an interferon-dependent tyrosine kinase, is physically associated with an interferon receptor. J. Biol. Chem. 1994, 269:3518-3522.
26. tyk2 tyrosine kinase. Mol. Cell. Biol. 1995, 14:8133-8142.
27. Cousens L.P., Orange J.S., Su H.C., Biron C.A. Interferon-α/β inhibition of interleukin-12 and interferon-γ production in vitro and endogenously during viral infection. Proc. Natl Acad. Sci. USA 1997, 94:634-639.
28. Creagan E.T., Ahmann D.L., Green S.J., et al. Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma. J. Clin. Oncol. 1984, 2:1002-1005.
29. Creagan E.T., Ahmann D.L., Green S.J., et al. Phase II study of recombinant leukocyte A interferon (rIFN-alpha A) in disseminated malignant melanoma. Cancer 1984, 54:2844-2849.
30. Croze E., Russell-Harde D., Wagner T.C., et al. The human type I interferon receptor. Identification of the interferon beta-specific receptor-associated phosphoprotein. J. Biol. Chem. 1996, 271:33165-33168.
31. Darnell J.E. STATs and gene regulation. Science 1997, 277:1630-1635.
32. Darnell J.E. Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. J. IFN Cytokine Res. 1998, 18:549-554.
33. Datta B., Min W., Burma S., Lengyel P. Increase in p202 expression during skeletal muscle differentiation: inhibition of MyoD protein expression and activity by p202. Mol. Cell. Biol. 1998, 18:1074-1083.
34. Der S.D., Yang Y.L., Weissman C., Williams B.R. A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. Proc. Natl Acad. Sci. USA 1997, 94:3279-3283.
35. Dever T.E., Chen J.J., Barber J.N., et al. Mammalian eukaryotic initiation 2a kinase functionally substitutes for GCN2 protein kinase in the GCN4 translational control mechanism of yeast. Proc. Natl Acad. Sci. USA 1993, 90:4616-4620.
36. Diaz M.O., Pomykala H.M., Bohlander S.K., et al. Structure of the human type I interferon gene cluster determined from a YAC clone contig. Genomics 1994, 22:540-552.
37. Domanski P., Witte M., Kellum M., et al. Cloning and expression of a long form of the β subunit of the interferon α receptor that is required for interferon signaling. J. Biol. Chem. 1995, 270:21606-21611.
38. Domanski P., Fish E., Nadean O.W., et al. A region of the β subunit of the interferon α receptor different from Box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state. J. Biol. Chem. 1997, 272:26388-26393.
39. Engelhardt O.G., Ullrich E., Kochs G., Haller O. Interferon-induced antiviral Mx1 GTPase is associated with components of the SUMO-1 system and promyelocytic leukemia protein nuclear bodies. Exp. Cell Res. 2001, 271:286-295.
40. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998, 352:1491-1497. European Study Group on Interferon β-1b in Secondary Progressive MS.
41. Fawaz L.M., Sharif-Askari E., Menezes J. Upregulation of NK cyotoxic activity via IL-15 induction by different viruses: a comparative study. J. Immunol. 1999, 163:4473-4480.
42. Field A.K., Tytell A.A., Lampson G.P., Hilleman M.R. Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes. Proc. Natl Acad. Sci. USA 1967, 58:1004-1010.
43. Furukawa Y., Iwase S., Kikuchi J., et al. Transcriptional repression of the E2F-1 gene by interferon-alpha is mediated through induction of E2F-4/pRB and E2F-4/p130 complexes. Oncogene 1999, 18:2003-2014.
44. Gartel A.L., Serfas M.S., Tyner A.L. p21-negative regulator of the cell cycle. Proc. Soc. Exp. Biol. Med. 1996, 213:138-149.
45. Gessani S., Belardelli F., Pecoreiil A., et al. Bacterial lipopolysaccharide and gamma interferon induce transcription of beta interferon mRNA and interferon secretion in murine macrophages. J. Virol. 1989, 63:2785-2789.
46. Ghosh A., Sarkar S., Sen G. A new isozyme-specific cellular effect of 2-5 (A) synthetase. J. IFN Cytokine Res. 1999, 19:S68.
47. Ghosh A., Sarkar S., Sen G. Cell growth regulatory and anti-viral effects of the P69 isozyme of 2-5 (A) synthetase. Virol. 2000, 266:319-328.
48. Gil J., Esteban M. The interferon-induced protein kinase (PKR), triggers apoptosis through FADD-mediated activation of caspase 8 in a manner independent of Fas and TNF-alpha receptors. Oncogene 2000, 19:3665-3674.
49. Gil J., Alcami J., Esteban M. Activation of NFκB by the ds-RNA-dependent protein kinase, PKR involves the IκB kinase complex. Oncogene 2000, 19:1369-1378.
50. Gilbert H. Long term treatment of myeloproliferative disease with interferon alpha2b: feasibility and efficacy. Cancer 1998, 83:1205-1213.
51. Golomb H.M., Jacobs A., Fefer A., et al. Alpha-2 interferon therapy for hairy-cell leukemia: a multicenter study of 64 patients. J. Clin. Oncol. 1986, 4:900-905.
52. Goodbourn S., Didcock L., Randall S.E. Interferons: cell signaling, immune modulation, antiviral responses and virus countermeasures. J. Gen. Virol. 2000, 81:2341-2364.
53. Gosselin J., Tomolu A., Gallo R.C., Flamand L. Interleukin-15 as an activator of natural killer cell-mediated antiviral response. Blood 1999, 94:4210-4219.
54. Gow P.J., Mutimer D. Treatment of chronic hepatitis. Br. Med. J. 2001, 323:1164-1167.
55. Gutterman J.U., Choubey D. Retardation of cell proliferation after expression of p202 accompanies an increase in p21 (WAF1/CIP1). Cell Growth Diff. 1999, 10:93-100.
56. Hagenbeek A., Carde P., Somers R., et al. Interferon-alfa-2a vs control as maintenance therapy for low grade non-Hodgkin’s lymphoma: results from a prospective randomized clinical trial. Proc. Am. Soc. Clin. Oncol. 1995, 14:386.
57. Harper J.W., Adami G.R., Wei N., et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75:805-816.
58. Hassel B.A., Zhou A., Sotomayor C., et al. A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. EMBO J. 1993, 12:3297-3304.
59. Hiddemann W., Unterhalt M., Koch P., et al. New aspects in the treatment of advanced low-grade non-Hodgkin’s lymphomas: prednimustine/mitoxantrone versus cyclophosphamide/vincristine/prednisone followed by interferon alfa versus observation only-a preliminary update of the German Low-Grade Lymphoma Study Group. Semin. Hematol. 1994, 31(Suppl. 3):32-35.
60. Hino K., Sainokami S., Shimoda K., et al. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J. Med. Virol. 1994, 42:299-305.
61. Hwang S.Y., Hertzog P.J., Holland K.A., et al. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. Proc. Natl Acad. Sci. USA 1995, 92:11284-11288.
62. Ihle J.N. The Janus protein tyrosine kinase family and its role in cytokine signaling. Adv. Immunol. 1995, 60:1-35.
63. 2-terminal kinase by double-stranded RNA and encephalomyocarditis virus: involvement of RNase L, protein kinase R and alternative pathways. Mol. Cell. Biol. 2000, 20:617-627.
64. Isaacs A., Lindenmann J. Virus interference. I. The interferon. Proc. R. Soc. (London), Ser. B. 1957, 147:258-273.
65. Iwase S., Furukawa Y., Kikuchi J., et al. Modulation of E2F activity is linked to interferon-induced growth suppression of hematopoietic cells. J. Biol. Chem. 1997, 272:12406-12414.
66. Jaramillo M.L., Abraham N., Bell J.C. The interferon system: a review with emphasis on the role of PKR in growth control. Cancer Invest. 1995, 13:327-338.
67. Johnson H.M., Bazer F.W., Szente B.E., Jarpe M.A. How interferons fight disease. Sci. Am. 1994, 270:68-75.
68. Johnstone R.W., Kerry J.A., Trapani J.A. The human interferon-inducible protein, IFI 16, is a repressor of transcription. J. Biol. Chem. 1998, 273:17172-17177.
69. Juang Y., Lowther W., Kellum M., et al. Primary activation of interferon A and interferon B gene transcription by interferon regulatory factor 3. Proc. Natl Acad. Sci. USA 1998, 95:9837-9842.
70. Kantarjian H.M., O’Brien S.M., Anderline P., Talpaz M. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 1996, 87:3069-3081.
71. Karpusas M., Nolte M., Benton C.B., et al. The crystal structure of human interferon beta at 2.2-A resolution. Proc. Natl Acad. Sci. USA 1997, 94:11813-11818.
72. Kaser A., Enrich B., Ludwiczek O., et al. Interferon-α (IFN-α) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway. Clin. Exp. Immunol. 1999, 118:71-77.
73. Kayagaki N., Yamaguchi N., Nakayama M., et al. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 1999, 189:1451-1460.
74. Kerr I.M., Brown R.E. pppA2’p5’A2’p5’A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells. Proc. Natl Acad. Sci. USA 1978, 75:256-260.
75. Kingsmore S.F., Snoddy J., Choubey D., et al. Physical mapping of a family of interferon-activated genes, serum amyloid P-component, and alpha-spcectrin on mouse chromosome 1. Immunogenetics 1989, 30:169-174.
76. Kirch H.C., Putzer B., Brockman D., et al. Formation of the early-region-2 transcription-factor-1-retino-blastoma-protein (E2F-1-RB) transrepressor and release of the retinoblastoma protein from nuclear complexes containing cyclin A is induced by interferon alpha in U937V cells but not in interferon-alpha-resistant U937VR cells. Eur. J. Biochem. 1997, 246:736-744.
77. Kirchoff S., Koromilas A.E., Schaper F., et al. IRF-1 induced cell growth inhibition and interferon induction requires the activity of the protein kinase PKR. Oncogene 1995, 11:439-445.
78. Kirkwood J.M. Interferon therapy: melanoma. Biologic Therapy of Cancer 1995, 388-411. JB Lippincott Co., Philadelphia. 2nd Edn. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
79. Koromilas A.E., Roy S., Barber G.N., et al. Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase. Science 1992, 257:1685-1689.
80. Kotenko S.V., Gallagher G., Baurin V.V., et al. IFNλs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 2003, 4:69-77.
81. Krown S.E., Real F.X., Cunningham-Rundles S., et al. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi’s sarcoma. N. Engl. J. Med. 1983, 308:1071-1076.
82. Krown S.E., Burk M.W., Kirkwood J.M., et al. Human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial. Cancer Treat. Rep. 1984, 68:723-726.
83. Kumar A., Yang Y.L., Flati V., et al. Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: role of IRF-1 and NF-kappaB. EMBO J. 1997, 16:406-416.
84. Labonnardière C., Martinat-Botte F., Terqui M., et al. Production of two species of interferon by large white and Meischan pig conceptuses during the peri-attachment period. Fertil. 1991, 91:469-478.
85. LaFleur D.W., Nardelli B., Tsareva T., et al. Interferonκ, a novel type I interferon expressed in human keratinocytes. J. Biol. Chem. 2001, 276:39765-39771.
86. Lane H.C., Kovacs J.A., Feinberg J., et al. Anti-retroviral effects of interferon-α in AIDS-associated Kaposi’s sarcoma. Lancet 1988, 2:1218-1222.
87. Lefévre F., Boulay V. A noel and atypical type one interferon gene expressed by trophoblast during early pregnancy. J. Biol. Chem. 1993, 268:19760-19768.
88. Legha S.S., Ring S., Eton O., et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J. Clin. Oncol. 1998, 16:1752-1759.
89. Lembo D., Angeretti A., Benefazio S., et al. Constitutive expression of the interferon-inducible protein p202 in NIH 3T3 cells affects cell cycle progression. J. Biol. Reg. Homeostat. Agents 1995, 9:42-46.
90. Leppert D., Waubant E., Burk M.R., et al. Inferferon beta-1b inhibits gelatinase secretion and in vitro migration human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 1996, 40:846-852.
91. Levy D.E., marie I., Smith E., Prakash A. Enhancement and diversification of IFN induction by IRF-7-mediated positive feedbach. J. IFN Cytokine Res. 2002, 22:87-93.
92. Ling L.E., Zafari M., Reardon D., et al. Human type I interferon receptor, IFNAR, is a heavily glycosylated 120-130 kD membrane protein. J. IFN Cytokine Res. 1995, 15:55-61.
93. Ling P.D., Warren M.K., Vogel S.N. Antagonistic effect of interferon-beta on the inteferon-gammainduced expression of la antigen in murine macrophages. J. Immunol. 1985, 135:1857-1863.
94. Lutfalla G., Holland S.J., Cinato E., et al. Mutant U5A cells are complemented by an inteferon-alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J. 1995, 14:5100-5108.
95. Mahon F.K., Fabères C., Pueyo S., et al. Response at three months is a good predictive factor for newly diagnosed chronic myelogenous leukemia patients treated by recombinant interferon-alpha. Blood 1998, 92:4059-5065.
96. Marie I., Durbin J.E., Levy D.E. Differential viral induction of distinct interferon-alpha genes by positive feedback through inteferon regulatory factor-7. EMBO J. 1998, 17:6660-6669.
97. Marrack P., Kappler J., Mitchell T. Type I inteferons keep activated T cells alive. J. Exp. Med. 1999, 189:521-530.
98. Martal J., Lacroix M.C., Loudes C., et al. Trophoblastin, an antiluteolytic protein present in early pregnancy in sheep. J. Reprod. Fertil. 1979, 56:63-73.
99. McLaughlin P., Cabanillas F., Hagemeister F.B., et al. CHOP-Bleo plus interferon for stage IV low-grade lymphoma. Ann. Oncol. 1993, 4:205-211.
100. Meinke A., Barahamand-Pour F., Wohrl S., et al. Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons. Mol. Cell. Biol. 1996, 16:6937-6944.
101. Miller A., Lanir N., Shapiro S., et al. Immunoregulatory effects of interferon-beta and interacting cytokines on human vascular endothelial cells. Implications for multiple sclerosis autoimmune diseases. J. Neuroimmunol. 1996, 64:151-161.
102. Min W., Ghosh S., Lengyel P. The interferon-inducible p202 protein as a modulator of transcription: inhibition of NF-kappa B, c-Fos and c-Jun activities. Mol. Cell. Biol. 1996, 16:359-368.
103. Mogensen E., Lewerenz M., Reboul J., et al. The type I interferon receptor: structure, function and evolution of family bisiness. J. IFN Cytokine Res. 1999, 19:1069-1098.
104. Moore R.N., Larsen H.S., Horohov D.W., Rouse B.T. Endogenous regulation of macrophage proliferative expansion by CSF-induced inteferon. Science 1984, 223:178-181.
105. Mori S., Jewett A., Cavalcanti M., et al. Differential regulation of human NK cell-associated gene expression following activation by IL-2, IFN-alpha and PMA/ionomycin. Int. J. Oncol. 1998, 12:1165-1170.
106. Mujtaba M.G., Streit W.J., Johnson H.W. IFN-tau suppresses both the autoreactive humoral and cellular immune responses and induces stable remission in mice with chronic experimental alergic encepehalomyelitis. Cell. Immunol. 1998, 186:94-102.
107. Müller U., Steinhoff U., Reis L.F.L., et al. Functional role of type I and type II interferons in antiviral defense. Science 1994, 264:1918-1921.
108. Nadeau O.W., Domanski P., Usacheva A., et al. The proximal tyrosines of the cytoplasmic domain of the β chain of the type I interferon receptor are eessential for signal transducer and activation of transcription (Stat) 2 activation. J. Biol. Chem. 1999, 274:4045-4052.
109. Novick D., Cohen B., Rubinstein M. The human interferon α/β receptor: characterization and molecular cloning. Cell 1994, 77:391-400.
110. O’Connell M.A., Krause S., Higuchi M., et al. Cloning of cDNAs encoding mammalian double-stranded RNA-specific adenosine deaminase. Mol. Cell. Biol. 1995, 15:1389-1397.
111. Ogasawara K., Hida S., Azimi N., et al. Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature 1998, 391:700-703.
112. Olek M.J., Smith D.J., Cook S.L., et al. Phase 1 study of oral recombinant ovine interferonτ in relapsingremitting multiple sclerosis. Neurology 2001, 56(Suppl. 3):A76.
113. Oritani K., Hirota S., Nakagawa T., et al. T-lymphocytes constitutively produce an interferonlike cytokine limitin characterized as a heat- and acid-stable and heparin-binding glycoprotein. Blood 2003, 101:178-185.
114. Oritani K., Medina K.L., Tomiyama Y., et al. Limitin: an interferon-like cytokine that preferentially influences B-lymphocyte precursors. Nat. Med. 2000, 6:659-666.
115. Ozer H., George S.L., Schiffer C.A., et al. Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival. Cancer and Leukemia Group B study 8583. Blood 1993, 82:2975-2984.
116. Ozer H., Wiernik P.H., Giles F., Tendler C. Recombinant interferon-alpha therapy in patients with follicular lymphoma. Cancer 1998, 82:1821-1830.
117. Patel R.C., Sen G.C. PACT, a protein activator of the interferon-induced protein kinase, PKR. EMBO J. 1998, 17:4379-4390.
118. Patterson J.B., Thomis D.C., Hans S.L., Samuel C.E. Mechanism of interferon action: double-stranded RNA-specific adenosine deaminase from human cells is inducible by alpha and gamma interferons. Virol. 1995, 210:508-511.
119. Peterson B.A., Petroni G.R., Oken M.M., et al. Cyclophosphamide versus cyclophophamide plus interferon alfa-2b in follicular low-grade lymphomas: an intergroup phase III trial (CALGB 8691 and EST 7486). Proc. Am. Soc. Clin. Oncol. 1997, 16:14a.
120. Platanias L.C., Fish E.N. Signaling pathways activated by interferons. Exp. Hematol. 1999, 27:1583-1592.
121. Platanias L.C., Uddin S., Colamonici O.R. Tyrosine phosphorylation of the α and β subunits of the type I interferon receptor. Interferon β selectively induces tyrosine phosphorylation of an α subunit associated protein. J. Biol. Chem. 1994, 27:17761-17764.
122. L subunits of the type I interferon receptor. J. Biol. Chem. 1996, 271:23630-23633.
123. Player M.R., Torrence P.F. The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation. Pharmacol. Ther. 1998, 78:55-113.
124. Polson A.G., Bass B.L. Preferential selection of adenosines for modification by double-stranded RNA adenosine deaminase. EMBO J. 1994, 13:5701-5711.
125. Pontzer C.H., Ott T.L., Bazer F.W., Johnson H.M. Localization of an antiviral site on the pregnancy recognition hormone, ovine trophoblast protein 1. Proc. Natl Acad. Sci. USA 1990, 87:5945-5949.
126. Pontzer C.H., Ott T.L., Bazer F.W., Johnson H.M. Structure/function studies with interferon tau: evidence for multiple active sites. J. Interferon Res. 1994, 14:133-141.
127. Porrini A.M., Gambi D., Reder A.T. Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J. Neuroimmunol. 1995, 61:27-34.
128. Poynard T., Marcellin P., Lee S.S., et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352:1426-1432.
129. Prejeah C., Colamonici O.R. Role of the cytoplasmic domains of the type I interferon receptor subunits in signaling. Semin. Cancer Biol. 2000, 10:83-92.
130. Price C.G., Rohatiner A.Z., Steward W., et al. Interferon-alpha 2b in the treatment of follicular lymphoma: preliminary results of a trial in progress. Ann Oncol. 1991, 2(Suppl. 2):141-145.
131. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998, 352:1498-1504. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group.
132. Quesada J.R., Reuben J., Manning J.T., et al. Alpha interferon for induction of remission in hairy-cell leukemia. N. Engl. J. Med. 1984, 310:15-18.
133. Quesada J.R., Hersh E.M., Manning J., et al. Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood 1986, 68:493-497.
134. Radhakrishnan R., Walter L.J., Hruza A., et al. Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography. Structure 1996, 4:1453-1463.
135. Radhakrishnan R., Walter L.J., Subramaniam P.S., et al. Crystal structure of ovine interferon-tau at 2.1 A resolution. J. Mol. Biol. 1999, 286:151-162.
136. Real F.X., Oettgen H.F., Krown S.E. Kaposi’s sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J. Clin. Oncol. 1986, 4:544-551.
137. Reddy K.R., Wright T.L., Poclros P.J., et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in non-cirrhotic patients with chronic hepatitis C. Hepatol. 2001, 33:433-438.
138. Regad T., Chelbi-Alix M.K. Role of fate of PML nuclear bodies in response to interferon and viral infections. Oncogene 2001, 20:7274-7286.
139. Reichman R.C., Oakes D., Bonnez W., et al. Treatment of condyloma acuminatum with three different alpha interferon preparations administered parenterally: a double-blind, placebo-controlled trial. Ann. Intern. Med. 1988, 108:675-679.
140. Reichman R.C., Oakes D., Bonnez W., et al. Treatment of condyloma acuminatum with three different alpha interferon preparations administered parenterally: a double-blind, placebo-controlled trial. J. Infect. Dis. 1990, 162:1270-1276.
141. Reis L.F.L., Lee T.H., Vilcek J. Tumor necrosis factor acts synergistically with autocrine interferon-β and increases interferon-β mRNA levels in human fibroblasts. J. Biol. Chem. 1989, 264:16351-16354.
142. Reiter Z. Interferon-major regulator of natural killer cell-mediated cytotoxicity. J. IFN Res. 1993, 13:247-257.
143. Remington J.S., Merigan T.C. Resistance to virus challenge in mice infected with protozoa or bacteria. Proc. Soc. Exp. Biol. Med. 1969, 131:1184-1188.
144. Rep M.H., Hintzen R.Q., Polman C.H., van Lier R.A. Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J. Neuroimmunol. 1996, 67:111-118.
145. Rep M.H., Schrijver H.M., van Lopik T., et al. Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-grammaproducing T cells in MS patients. J. Neuroimmunol. 1999, 96:92-100.
146. Richards J.M., Gale D., Mehta N., Lestingi T. Combination of chemotherapy with interleukin-2 and interferon for the treatment of metastatic melanoma. J. Clin. Oncol. 1999, 17:651-657.
147. Rothmann S.A., Paul P., Oluic’ T.J., et al. Chronic induction of interferon by continuous infusion of polyriboinosinic: polyribocytidilic acid. J. IFN Res. 1985, 5:273-278.
148. Rysiecki G., Gewert D.R., Williams B.R. Consititutive expression of a 2’,5’-oligoadenylate synthetase cDNA results in incureased antiviral activity and growth suppression. J. IFN Res. 1989, 9:649-657.
149. Saelens X., Kalai M., Vandenabeele P. Translation inhibition in apoptosis. J. Biol. Chem. 2001, 276:41620-41628.
150. Sanceau J., Hiscott J., Delattre O., Wietzerbin J. IFN-beta induces serine phosphorylation of Stat-1 in Ewing’s sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7. Oncogene 2000, 19:3372-3383.
151. Sangfelt O., Erickson S., Einhorn S., Grandér D. Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-alpha in hematopoietic cell lines. Oncogene 1997, 14:415-423.
152. Sangfelt O., Erickson S., Castro J., et al. Molecular mechanisms underlying interferon-a-induced G0/G1 arrest: CK1-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene 1999, 18:2798-2810.
153. Satoh J., Paty D.W., Kim S.U. Differential effects of beta and gamma interferons on expression of major histocompatibility complex antigens and intercellular adhesion molecule-1 in cultured fetal human astrocytes. Neurology 1995, 45:367-373.
154. Scadden A.D., Smith C.W. A ribonuclease specific for inosine-containing RNA: a potential role in antiviral defence?. EMBO J. 1997, 16:2140-2149.
155. Schaller B., Radziwill A.J., Steck A.J. Successful treatment of Guillain-Barré syndrome with combined administration of interferon-beta-1a and intravenous immunoglobulin. Eur. Neurol. 2001, 46:167-168.
156. Senda T., Saitoh S.I., Mitsui Y. Refined crystal structure of recombinant murine interferon-b at 2.15 A resolution. J. Mol. Biol. 1995, 253:187-207.
157. Sheppard P., Kindsvogel W., Xu W., et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 2003, 4:63-68.
158. Smalley R.V., Andersen J.W., Hawkins M.J., et al. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin’s lymphoma. N. Engl. J. Med. 1992, 327:1336-1341.
159. Solal-Celigny P., Lepage E., Brousse N., et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Group d’Etude des Lymphomes de l’Adulte. N. Engl. J. Med. 1993, 329:1608-1614.
160. Solal-Celigny P., Lepage E., Brousse N., et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Group d’Etude des Lymphomes Folliculaires 86 Trial. J. Clin. Oncol. 1993, 16:2332-2338.
161. Soos J.M., Johnson H.M. Interferon-tau: prospects for clinical use in autoimmune diseases. Biodrugs 1999, 11:125-135.
162. Soos J.M., Subramaniam P.S., Hobeika A.C., et al. The IFN pregnancy recognition hormone IFN-tau blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity. J. Immunol. 1995, 155:2747-2753.
163. Soos J.M., Mujtaba M.G., Subramaniam P.S., et al. Oral feeding of interferontau can prevent the acute and chronic relapsing forms of experimental allergic encephalomyelitis. J. Neuroimmunol. 1997, 75:43-50.
164. Staehli P., Grob R., Meier E., et al. Influenza virus-susceptible mice carry Mx genes with a large deletion or a nonsense mutation. Mol. Cell. Biol. 1988, 8:4518-4523.
165. Staehli P., Pitossi F., Pavlovic J. Mx proteins: GTPases with antiviral activity. Trends Cell Biol. 1993, 3:268-272.
166. Stark G.R., Kerr I.M., Williams B.R.G., et al. How cells respond to interferons. Ann. Rev. Biochem. 1998, 67:227-264.
167. Stranden A.M., Staehli P., Pavlovic J. Function of the mouse Mx1 protein is inhibited by overexpression of the PB2 protein of influenza virus. Virol. 1993, 197:642-651.
168. Stuve O., Dooley N.P., Uhm J.H., et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 1996, 40:853-863.
169. Subramaniam P.S., Johnson H.M. A role for the cyclin-dependent kinase inhibitor p21 in the G1 cell cycle arrest mediated by the type I interferons. J. IFN Cytokine Res. 1997, 17:11-15.
170. Subramaniam P.S., Cruz P.E., Hobeika A.C., Johnson H.M. Type I interferon induction of the Cdk-inhibitor p21WAF1 is accompanied by ordered G1 arrest, differentiation and apoptosis of the Daudi B-cell line. Oncogene 1998, 16:1885-1890.
171. Takahashi I., Kosaka H., Oritani K., et al. A new IFN-like cytokine, limitin modulates the immune response without influencing thymocyte development. J. Immunol. 2001, 167:3156-3163.
172. Takizawa T., Ohashi K., Nakanishi Y. Possible involvement of double-stranded RNA-activated protein kinase in cell death by influenza virus infection. J. Virol. 1996, 70:8128-8132.
173. Talpaz M., McCredie K.B., Mavligit G.M., Gutterman J.U. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983, 62:689-692.
174. Talpaz M., Kantarjian H.M., McCredie K., et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogeneous leukemia. N. Engl. J. Med. 1986, 314:1065-1069.
175. Talpaz M., Kurzrock R., Kantarjian H., et al. Recombinant IFN-alpha therapy of chromosome-negative myeloproliferative disorders with thrombocytosis. Am. J. Med. 1989, 86:554-558.
176. Tanaka N., Sato M., Lamphier M.S., et al. Type I interferons are essential mediators of apoptotic death in virally infected cells. Genes Cells 1998, 3:29-37.
177. Taniguchi T., Takaoka A. A weak signal for strong responses: interferon-α/β revisited. Nature Rev. Mol. Cell. Biol. 2001, 2:378-386.
178. Taniguchi T., Takaoka A. The interferon α/β system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr. Opin. Immunol. 2002, 14:111-116.
179. Tennakoon D.K., Smith R., Stewart M.D., et al. Ovine IFN-tau modulates the expression of MHC antigens on murine cerebrovascular endothelial cells and inhibits replication of Theiler’s virus. J. IFN Cytokine Res. 2001, 21:785-792.
180. Thacore H.R., Youngner J.S. Different sensitivity of ribonucleic and deoxyribonucleic acid viruses to resistance induced in rabbit cells (RK-13) by polyriboinosinic acid-polyribocytidilic acid. Infect. Immun. 1973, 7:685-690.
181. Tough D.F., Borrow P., Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996, 272:1947-1950.
182. Tyring S.K. Treatment of condyloma acuminatum with interferon. Semin. Oncol. 1988, 15:35-40.
183. Tytell A.A., Lampson G.P., Field A.K., Hilleman M.R. Inducers of interferon and host resistance. III. Double-stranded RNA from reovirus type 3 virions (reo 3-RNA). Proc. Natl Acad. Sci. USA 1967, 58:1719-1722.
184. Uddin S., Lekmine F., Sharma N., et al. The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon α-dependent transcriptional activation but not serine phosphorylation of Stat proteins. J. Biol. Chem. 2000, 275:27634-27640.
185. Uddin S., Sassano A., Deb D.K., et al. Protein kinase C delta (PKCδ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J. Biol. Chem. 2002, 277:14408-14416.
186. Unterhalt M., Herrmann R., Nahler M., et al. Significant prolongation of disease-free survival in advanced low grade non-Hodgkin’s lymphomas (NHL) by interferon alfa maintenance. Blood 1995, 86:439a.
187. Unterhalt M., Herrmann R., Tiemann M., et al. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin’s lymphoma. German Low-Grade Lymphoma Study Group. Leukemia 1996, 10:836-843.
188. Uzé G., Lutfalla G., Gresser I. Genetic transfer of a functional human interferon receptor into mouse cells: cloning and expression of its cDNA. Cell 1990, 60:225-234.
189. Verma D.S., Spitzer G., Gutterman J.U., et al. Human leukocyte interferon preparation blocks granulopoietic differentiation. Blood 1979, 54:1423-1427.
190. Wang H., Liu C., Lu Y., et al. The interferon- and differentiation-inducible p202a protein inhibits the transcriptional activity of c-Myc by blocking its association with Max. J. Biol. Chem. 2000, 275:27377-27385.
191. Weigent D.A., Huff T.L., Peterson J.W., et al. Role of interferon in streptococcal infection in the mouse. Microb. Pathog. 1986, 1:399-407.
192. Weissman C., Weber H. The interferon genes. Prog. Nucl. Acid Res. 1986, 33:251-300.
193. Williams B.R.G. PKR: a sentinel kinase for cellular stress. Oncogene 1999, 18:6112-6120.
194. Yanase N., Ohshima K., Ikegami H., Mizuguchi J. Cytochrome c release, mitochondrial membrane depolarization, caspase-3 activation, and Bax-alpha cleavage during IFN-alpha-induced apoptosis in Daudi B lymphoma cells. J. IFN Cytokine Res. 2000, 20:1121-1129.
195. Yang Y.L., Reis L.F., Pavlovic J., et al. Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. EMBO J. 1995, 14:6095-6106.
196. Yeung M.C., Chang D.L., Camantigue R.E., Lau A.S. Inhibitory role of the host apoptogenic gene PKR in the establishment of persistent infection by encephalomyocarditis virus in U937 cells. Proc. Natl Acad. Sci. USA 1999, 96:11860-11865.
197. Yoneyama M., Suhara W., Fujita T. Review: Control of IRF-3 activation by phosphorylation. J. IFN Cytokine Res. 2002, 22:73-76.
198. Zhang X., Sun S., Hwang I., et al. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 1998, 8:591-599.
199. Zhou A., Paranjape J.M., Hassel B.A., et al. Impact of RNase L overexpression on viral and cellular growth and death. J. IFN Cytokine Res. 1998, 18:953-961.
200. Zhou A., Paranjape J.M., Der S.D., et al. Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways. Virology 1999, 258:435-440.